Sign Up
Stories
Healthcare Dealmakers Optimistic for More Deals
Share
AbbVie's Healthcare Acquisitions
Amgen and Pfizer Complete Acquisitions b...
Amgen to Lay Off Horizon Employees After...
BioRestorative Therapies Inc (BRTX) Stoc...
Biotech Investment Amidst Rate Cuts
Biotech Stocks Shine Despite Challenges
Overview
API
Healthcare dealmakers are anticipating more deals following a wave of biotech company takeovers, with the JPMorgan Healthcare Conference in San Francisco set to attract over 8,000 attendees. Last month, drugmakers announced roughly $25 billion worth of U.S.-listed biotech deals, reflecting a 8% growth in global healthcare M&A activity in 2023. The conference will cover topics such as weight-loss drugs, regulation, antitrust, financing environment, and potential effects of the 2024 U.S. presidential election on the industry.
Ask a question
How might the anticipated deals impact the healthcare industry's competitive landscape?
What are the potential implications of the 2024 U.S. presidential election on the healthcare industry?
What regulatory trends might be discussed at the JPMorgan Healthcare Conference, and how could they influence future business decisions?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Coverage